Kevin Yee

1.4k citations
12 papers · 1.2k indexed · 1 hit paper · h-index 9

Impact in

  • Hematology top 2%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 5%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

    • Chronic Myeloid Leukemia Treatments 6
    • Acute Myeloid Leukemia Research 5
    • Chronic Lymphocytic Leukemia Research 2

Kevin Yee

12 papers receiving 1.2k citations

Hit Papers

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo 2003 · 703 citations
7032003202620102018200400600

Peers

Kevin Yee
Comparison fields: 5 of 67
  • Hematology 499
  • Genetics 267
  • Gastroenterology 89
  • Oncology 303
  • Pulmonary and Respiratory Medicine 362
Replace Joseph M. Gozgit with:
Joseph M. Gozgit United States
Sharianne G. Louie United States
Steven Novick United States
Paola Aimone Switzerland
Mary Jo Lehman United States
Paul K. Stockman United Kingdom
Toshiki Iwai Japan
Anne-Marie O’Farrell United States
Darrin M. Beaupre United States
Ron Paquette United States
Kevin Yee relative to Joseph M. Gozgit United States Joseph M. Gozgit's profile →
Citations per field
00.5×1.5×2.4×
Joseph M. Gozgit · 1×
Citations per year

Countries citing papers authored by Kevin Yee

Since Specialization
Citations

This map shows the geographic impact of Kevin Yee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Yee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Yee more than expected).

Fields of papers citing papers by Kevin Yee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Yee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Yee. The network helps show where Kevin Yee may publish in the future.

Co-authors

The 25 scholars most cited alongside Kevin Yee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kevin Yee Line = papers co-authored together Kevin Yee links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1 20221
2 20206
3 200932
4 200636
5 200459
6 2004103
7 200355
8
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
Hit paper breakdown →
2003703
9
Cancers of the gallbladder and biliary ducts.
200228
10 2002140
11 20003
12 199931

About Kevin Yee

Kevin Yee is a scholar working on Hematology, Genetics, Pharmacology, Rheumatology and Endocrinology, Diabetes and Metabolism, having authored 12 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (6 papers), Acute Myeloid Leukemia Research (5 papers), Chronic Lymphocytic Leukemia Research (2 papers), Eosinophilic Disorders and Syndromes (2 papers), Cystic Fibrosis Research Advances (2 papers), Neonatal Respiratory Health Research (2 papers), Pharmacogenetics and Drug Metabolism (2 papers) and Hormonal Regulation and Hypertension (2 papers). The work is most often cited by research in Hematology (499 citations), Genetics (267 citations), Gastroenterology (89 citations), Oncology (303 citations) and Pulmonary and Respiratory Medicine (362 citations). Kevin Yee has collaborated with scholars based in United States, Germany and Puerto Rico. Frequent co-authors include Michael C. Heinrich, Julie M. Cherrington, Ajia Town, Beverly D. Smolich, Lesley Murray, Sharianne G. Louie, William C. Manning, Leslie B. Lee, Tinya J. Abrams and Laura McGreevey. Their work appears in journals such as Blood, Human Mutation, Bioorganic & Medicinal Chemistry, Cell Cycle and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026